Chintan Shivir in Ahmedabad focuses on scaling pharma exports as India crosses $30 billion mark

1. At a Glance

• Chintan Shivir industry interaction on theme "Scaling up Pharma Exports" held in Ahmedabad on 21 Feb 2026 by the Department of Commerce with PHARMEXCIL [S1][S2].
• Convened against the milestone of India's pharma exports crossing USD 30 billion (USD 30.47 bn in FY 2024-25, +9.4% YoY); industry target = double-digit growth in 2026-27 [S1][S2].
• Flagged the ₹10,000 crore Biopharma SHAKTI initiative to build biologics/biosimilars capacity and cut import dependence [S1][S2].
• Examinable as a GS-III economy/industry hook bridging PLI-Pharma, biotech policy, trade diplomacy and India's "Pharmacy of the World" branding.

2. Why in the News

• Industry interaction held 21 February 2026 in Ahmedabad under the PM-guided Chintan Shivir series, focused on scaling pharma exports past the USD 30 bn mark [S1].
• Coincides with Budget 2026-27 announcement of Biopharma SHAKTI by Dr. Jitendra Singh [S2].

3. Background & Evolution

• Chintan Shivir format = government-industry brainstorming sessions used across ministries since 2022 to align policy with stakeholders.
• Pharma export trajectory: USD 26.5 bn (FY 2023-24) → USD 30.47 bn (FY 2024-25), growth of 9.4% [S1][S2].
• India: 3rd globally by volume, 11th by value (2023); exports to >200 countries; >60% to stringent regulatory markets (US, EU, Japan, Canada, Australia) [S1][S2].
• Predecessor pushes: PLI Scheme for Pharmaceuticals (2021), Bulk Drug Parks scheme, National Biopharma Mission.

4. Core Static Facts

• Event: Chintan Shivir – "Scaling up Pharma Exports", Ahmedabad, 21 Feb 2026 [S1].
• Organisers: Ministry of Commerce & Industry – Department of Commerce, with Pharmaceutical Export Promotion Council of India (PHARMEXCIL) [S1][S2].
• FY 2024-25 pharma exports: USD 30.47 billion; growth 9.4% [S1].
• Biopharma SHAKTI: outlay ₹10,000 crore over 5 years (Budget 2026-27) [S1][S2].
• Strategic target: 5% of global biopharmaceutical market share [S1].
• Market mix: US ~34%, Europe ~19% of pharma exports [S2].
• Sector base: ~3,000 companies, 10,500 manufacturing units, >60,000 generic brands, 60 therapeutic areas [S2].
• Aim 2026-27: double-digit export expansion [S1].

5. Multi-Dimensional Analysis

Economic - Pharma is a flagship export sector contributing to current account; double-digit growth target aligns with national export goal of USD 2 trillion by 2030. - Shift sought from volume-driven generics to higher-value biologics, biosimilars, innovation products [S1].

Scientific / Technological - Biopharma SHAKTI to plug capability gap in biologics where India lags vs US/EU; targets end-to-end ecosystem from R&D to manufacturing [S1][S2]. - Complements PLI-Pharma and PRIP (Promotion of Research & Innovation in Pharma MedTech).

Geopolitical / Strategic - 60%+ exports to stringent regulators → soft-power leverage; >200 country footprint sustains "Pharmacy of the Global South" tag [S1]. - US dependency (~34%) is a tariff-risk vector amid 2026 trade frictions [S2].

Administrative / Governance - Chintan Shivir model institutionalises regulator-industry coordination (CDSCO, DoP, DoC) for faster, predictable approvals [S1]. - Federal axis: DoC (exports) + Department of Pharmaceuticals (DoP, under M/o Chemicals & Fertilizers) + DBT (biologics).

6. Recent Developments (last 12-18 months)

• Feb 2026: Chintan Shivir Ahmedabad on pharma exports [S1].
• Budget 2026-27: Biopharma SHAKTI (₹10,000 cr) + 3 dedicated chemical parks announced [S2].
• 2025: Pharma exports cross USD 30 bn for first time (FY 2024-25) [S1].
• Earlier 2026: Department of Commerce held parallel Chintan Shivir on Medical Devices export ecosystem [S2].

7. Prelims Hooks

• Pharma exports FY 2024-25 = USD 30.47 billion; growth 9.4% [S1].
• Chintan Shivir on pharma exports held in Ahmedabad on 21 Feb 2026 [S1].
• Organised by Department of Commerce (Ministry of Commerce & Industry), not Department of Pharmaceuticals [S1].
• Partner body: PHARMEXCIL (Pharmaceutical Export Promotion Council of India) [S2].
• Biopharma SHAKTI outlay = ₹10,000 crore over 5 years [S1].
• Target global biopharma market share = 5% [S1].
• India ranks 3rd by volume in global pharma production [S2].
• India's medicines reach >200 countries; >60% exports to stringent regulated markets [S1].
• US share of India's pharma exports ~34%; Europe ~19% [S2].
• Industry export-growth aim for 2026-27: double-digit [S1].
• Chintan Shivir is a government-industry interaction format, not a statutory body.
• Manufacturing units in India: ~10,500; therapeutic areas covered: 60 [S2].

8. Mains Relevance

• GS-III: Indian Economy – Growth, Development, Employment; Industrial Policy; Science & Tech indigenisation.
• Syllabus: "Effects of liberalization on the economy"; "Achievements of Indians in S&T; indigenization of technology".
• Plausible stems: 1. "India's pharma sector has graduated from being the 'pharmacy of the world' in generics to a contender in biologics. Examine the role of initiatives like Biopharma SHAKTI in this transition." (15 marks) 2. "Discuss the structural challenges in scaling India's pharmaceutical exports beyond USD 30 billion and suggest a policy roadmap." (10 marks) 3. "Industry-government consultative formats like Chintan Shivir reflect a shift in India's economic governance. Critically evaluate." (10 marks)

9. Related Topics to Study Next

• PLI Scheme for Pharmaceuticals & Bulk Drugs — sister policy on import substitution in APIs.
• PRIP Scheme — R&D incentive layer for pharma/MedTech.
• National Biopharma Mission (DBT) — predecessor to Biopharma SHAKTI.
• CDSCO & Drug regulation — approval bottlenecks cited in the Shivir.
• Jan Aushadhi (PMBJP) — domestic affordability counterpart to export push.
• TRIPS & compulsory licensing — IP regime shaping biosimilars trade.
• Bulk Drug Parks scheme — 3 parks (HP, Gujarat, AP).
• Medical Devices Policy 2023 — parallel Chintan Shivir held on this.

10. Common Errors / Trap Areas

• Ministry confusion: Chintan Shivir was by Department of Commerce (M/o Commerce & Industry), NOT Department of Pharmaceuticals (M/o Chemicals & Fertilizers).
• Biopharma SHAKTI outlay: ₹10,000 crore (one PIB note mentions ₹13,000 cr combined with chemical parks — don't conflate).
• Volume vs Value rank: India is 3rd by volume but only ~11th by value globally — easy MCQ trap.
• Export figure: FY 2024-25 is USD 30.47 bn, not "USD 27.8 bn" (that was FY 2023-24 mid-year estimate).
• Chintan Shivir is a format/series, not a statutory scheme or one-off event — earlier Shivirs covered MHA, Defence, Medical Devices etc.

11. Sources

• [S1] Chintan Shivir in Ahmedabad focuses on scaling pharma exports as India crosses $30 billion mark — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2231234 — (tier: 1)
• [S2] Biopharma SHAKTI / Budget 2026-27 announcements & India Pharma profile — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2221778 ; https://www.pib.gov.in/PressReleasePage.aspx?PRID=2222079 ; https://static.pib.gov.in/WriteReadData/specificdocs/documents/2026/feb/doc202622776701.pdf — (tier: 1)